SLC29A2 and brain neoplasm: In this mechanistic and proof-of-concept study, we investigated the ability of a reengineered and optimized fragment of 3E10, Deoxymab-1 (DX1), to penetrate brain endothelial cells and cross the BBB in an ENT2-dependent manner, and to target and suppress the growth of orthotopic brain tumors.